引用本文: |
王璐瑶,张培彤,林月洁,罗钺,黄蓉,王菁.于数据挖掘和网络药理学探讨肺癌化疗后骨髓抑制的用药规律及作用机制[J].湖南中医药大学学报,2022,42(3):418-424[点击复制] |
|
|
|
本文已被:浏览 2368次 下载 613次 |
于数据挖掘和网络药理学探讨肺癌化疗后骨髓抑制的用药规律及作用机制 |
王璐瑶,张培彤,林月洁,罗钺,黄蓉,王菁 |
(北京中医药大学, 北京 100029;中国中医科学院广安门医院, 北京 100053) |
摘要: |
目的 探究中药防治肺癌化疗后骨髓抑制的用药规律及核心药物潜在作用机制。方法 检索中国知网、万方、维普数据库自建库以来关于中药防治肺癌化疗后骨髓抑制的文献,运用IBM SPSS Statistics 24.0、IBM SPSS Modeler 18.0软件进行数据挖掘,总结用药规律,筛选核心药对,利用网络药理学方法分析其潜在作用机制。结果 (1)共纳入62篇文献,包含62个处方、153味中药;(2)使用频次最高的10味中药依次是黄芪、白术、甘草、当归、茯苓、党参、熟地黄、白芍、女贞子、鸡血藤,以补虚药为主,补气药最多,补血药次之,主要归于脾、肺、肾三经,以甘、苦、辛味居多,药性多温、平;(3)筛选得到核心药对为“黄芪-白术”,其主要通过槲皮素、山柰酚、芒柄花素、异鼠李素等成分作用于PTGS2、NOS3、MAPK14、RELA、GSK3B等疾病靶点,调控PI3K-Akt、MAPK、TNF、IL-17等信号通路刺激造血干细胞分化,发挥造血功能。结论 中药治疗肺癌化疗后骨髓抑制以补益脾肺为核心,以补气、补血为主,药物通过多成分、多靶点、多通道对化疗后骨髓抑制发挥作用。 |
关键词: 肺癌 化疗 骨髓抑制 中药 数据挖掘 网络药理学 用药规律 |
DOI:10.3969/j.issn.1674-070X.2022.03.013 |
投稿时间:2021-06-10 |
基金项目:国家自然科学基金项目(81673797)。 |
|
Explore the drug rule and action mechanism of bone marrow suppression after lung cancer chemotherapy based on data mining and network pharmacology |
WANG Luyao,ZHANG Peitong,LIN Yuejie,LUO Yue,HUANG Rong,WANG Jing |
(Beijing University of Chinese Medicine, Beijing 100029, China;Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing 100053, China) |
Abstract: |
Objective To explore the regularity and potential mechanism of core drugs of Chinese medicine in the prevention and treatment of bone marrow suppression after chemotherapy of lung cancer. Methods The literatures on Chinese medicine for prevention and treatment of bone marrow suppression after chemotherapy of lung cancer since the establishment of CNKI, Wanfang and Weipu databases were searched, IBM SPSS Statistics 24.0 and IBM SPSS Modeler 18.0 were used for data mining, medication rule was summarized, and core drug pairs were screened. Network pharmacology method was used to analyze its potential mechanism of action. Results (1) A total of 62 literatures were included, including 62 prescriptions and 153 traditional Chinese medicines; (2) The 10 most frequently used Chinese medicines were Huangqi (Astragali Radix), Baizhu (Atractylodis Macrocephalae Rhizoma), Gancao (Glycyrrhizae Radix Et Rhizoma), Danggui (Angelicae Sinensis Radix), Fuling (Poria), Dangshen (Codonopsis Radix), Shudihuang (Rehmanniae Radix Praeparata), Baishao (Paeoniae Radix Alba), Nvzhenzi (Ligustri Lucidi Fructus), Jixueteng (Spatholobi Caulis). Tonic drugs were the main ones, the Qi-tonifying drugs were the most, and the blood-tonifying drugs were the second, and they were mainly attributed to the three meridians of the spleen, lung and kidney. They were mostly sweet, bitter and pungent. The property was mainly temperature and flat. (3) The core drug pair selected as “Huangqi (Astragali Radix)-Baizhu (Atractylodis acrocephalae Rhizoma)”, mainly through quercetin, kaempferol, formononetin, isorhamnetin and other ingredients to act on PTGS2, NOS3, MAPK14, RELA, GSK3B and other disease targets, regulate PI3K-Akt, MAPK, TNF, IL-17 signaling pathway and other pathways to stimulate hematopoietic stem cell differentiation and perform hematopoietic function. Conclusion The treatment of bone marrow suppression after chemotherapy of lung cancer with traditional Chinese medicine focus on tonifying the spleen and lung, mainly tonifying Qi and blood. The drugs play a role in treating bone marrow suppression after chemotherapy through multi-component, multi-target and multi-channel. |
Key words: lung cancer chemotherapy bone marrow suppression traditional Chinese medicine data mining network pharmacology medication rules |
|
 二维码(扫一下试试看!) |
|
|
|
|